Develop solutions

Dedicated to providing IQVIA multinational pharmaceutical enterprises in China with high quality clinical management services.Over the past 20 years, IQVIA with local hospitals, researchers and regulators established close relations of cooperation.Through integration of local resources and technology, global cooperation IQVIA industry leading professional knowledge was applied to different disease areas, high quality complete clinical trials, faster to promote products market access, and accelerate the market popularity.Take root in China over the past 20 years, IQVIA using the successful experience also help local companies effectively promote drug development.

The advantage of IQVIA (greater China)

Industry elite and expert network

Global operations CRO, into China for more than 20 years
Distribution in 22 cities, about 2200 employees
More than 300 biometric data management/drug safety full-time employees, more than 280 employees
Located at the data center, provides four language backend support (Chinese/English/Japanese/Korean)
Strategic cooperation with 15 research center

Rich successful cases and experience

Three kinds of delivery mode (GDU/CBU kunduz extension),
Meet the needs of multinational and local pharmaceutical companies
More than 300 patients with primary disease research (since 2007)
Recruit about 50000 patients (since 2007)
Submit to the CFDA more than 120 NDA and IND

Universal coverage major disease areas

IQVIA centre of excellence in the field of global operates 14 major disease, focused service in the corresponding field

Characteristics of coe

Cell and gene therapy

Cells, and the rapid development of gene therapy to subvert the whole of the health ecosystem, people need to review and development, management, product value and reimbursement.IQVIA will vigorously boost the development of new therapies and commercialized, and fully prepared for the next step.

For details

Develop solutions